AMLX News and Press, Amylyx Pharmaceuticals Inc.

Last participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on track; anticipated in Q3 2026 LUCIDITY is evaluating the FDA-agreed-upon primary outcome of reduction in the composite of Level 2...

2026-03-04 18:03:30 ET The last time I spoke about Amylyx Pharmaceuticals ( AMLX ) it was with respect to a Seeking Alpha article entitled " Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along ." With respect to this article, I noted that the company was in...

2026-03-03 16:33:31 ET More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript Amylyx Pharmaceuticals: Back From The Dead Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcr...

2026-03-03 16:32:51 ET Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call March 3, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript

2026-03-03 09:40:23 ET Image source: The Motley Fool. Tuesday, March 3, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-03-03 07:17:12 ET More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals: Back From The Dead Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Amylyx Pharmaceuticals Q4 2025 Earnings Preview Seeking A...

Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization...

GitLab Inc. (GTLB) is expected to report $-0.02 for Q4 2026 Ross Stores Inc. (ROST) is expected to report $1.88 for Q4 2026 Advantage Solutions Inc. (ADV) is expected to report $0.07 for Q4 2025 Hyster-Yale Inc. Class A (HY) is expected to report $-1.2 for Q4 2025 Versant Media Gr...

2026-03-02 17:35:38 ET More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals: Back From The Dead Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Seeking Alpha’s Quant Rating on Amylyx Pharmaceuticals ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m. ET...